Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Strong Trading Volume – Should You Buy?

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares saw unusually-high trading volume on Monday . Approximately 1,480 shares were traded during mid-day trading, an increase of 9% from the previous session’s volume of 1,360 shares.The stock last traded at $63.19 and had previously closed at $66.84.

Analyst Ratings Changes

Several research analysts have commented on ZLDPF shares. BTIG Research upgraded shares of Zealand Pharma A/S to a “strong-buy” rating in a research report on Friday, November 28th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a research report on Tuesday, December 16th. Six investment analysts have rated the stock with a Strong Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Strong Buy”.

Zealand Pharma A/S Trading Up 2.8%

The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.10 and a current ratio of 14.10. The business has a 50 day simple moving average of $75.57 and a 200-day simple moving average of $69.04. The stock has a market capitalization of $4.64 billion, a P/E ratio of 4.57 and a beta of 0.74.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last announced its earnings results on Thursday, November 13th. The company reported ($0.90) earnings per share for the quarter, beating the consensus estimate of ($1.11) by $0.21. Zealand Pharma A/S had a return on equity of 55.76% and a net margin of 71.79%.The business had revenue of $7.76 million during the quarter, compared to analysts’ expectations of $4.54 million. On average, analysts predict that Zealand Pharma A/S will post -2.19 EPS for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.